Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 24, 2023
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
[ Fri, Feb 24th 2023
] - WOPRAI
Thu, February 23, 2023
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
[ Thu, Feb 23rd 2023
] - WOPRAI
Jeff Johnson Maintained (TNDM) at Hold with Decreased Target to $40 on, Feb 23rd, 2023
Jeff Johnson of Baird, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Hold with Decreased Target from $45 to $40 on, Feb 23rd, 2023.
Jeff has made no other calls on TNDM in the last 4 months.
There are 3 other peers that have a rating on TNDM. Out of the 3 peers that are also analyzing TNDM, 2 agree with Jeff's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mike Polark of "Wolfe Research" Initiated at Hold on, Thursday, January 26th, 2023
- Larry Biegelsen of "Wells Fargo" Upgraded from Sell to Hold and Held Target at $43 on, Tuesday, November 15th, 2022
This is the rating of the analyst that currently disagrees with Jeff
- Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $52 on, Friday, November 4th, 2022
